First-line therapies for RA include nonsteroidal anti-inflammatory drugs and small-molecule disease-modifying antirheumatic agents such as methotrexate; however, there is a growing role for biological agents, including tocilizumab, a humanized anti-IL-6 receptor antibody [14] that blocks IL-6 signaling. The gene discussed is IL6; the disease is rheumatoid arthritis.